Geographically North America dominated global liver disease treatment market driven by best in the class healthcare infrastructure, advanced facilities and awareness and higher spending by the citizens towards healthcare expenditure. North America was followed by Europe and Asia-Pacific as second and third largest market for liver disease treatment market. Asia Pacific is projected to have fastest growth, owing to rapidly increasing healthcare infrastructure, increased spending, government initiatives and increasing awareness amongst population, and growing medical tourism industry in developing nations such as China, and India in this region.
This report identifies the global liver disease treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the market drivers, restraints, growth indicators, challenges, and other key aspects with respect to global liver disease treatment market.
This report segments global liver disease treatment market on the basis of treatment, disease, end-user and regional market as follows:
Liver Disease Treatment Market, By Drug Type: Vaccines, Antiviral, Corticosteroids, Anabolic Steroids, Antimetabolites, Anti-Rejection Drugs, Immunosuppressive Agents, Immune Globulins and Chemotherapy
Liver Disease Treatment Market, By Disease Hepatitis, Autoimmune Diseases, Liver Tumor, Alcohol Induced Liver Disease, Chronic Liver Disease and Non-Alcoholic Fatty Liver Disease
Liver Disease Treatment Market, By End-Usert: Hospitals, Adult Liver Disease Treatment Centers, Ambulatory Surgical Centers
This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region
This report identifies all the major companies operating in the liver disease treatment market. Some of the major companies’ profiles in detail are as follows:
Bayer Schering AG
Glaxosmithkline PlC, Merck & Co.
Zydus Pharmaceuticals Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.3. Product Benchmarking
3.4. End User Profiling
3.5. Top 5 Financials Analysis
4. Liver Disease Treatment Market– Market Forces
4.1.1. Growing prevalence of Hepatitis A, B and C
4.2.1. Inadequate number of donors
4.3.1. Emerging economies
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition
5. Liver Disease Treatment Market– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors
6. Liver Disease Treatment Market, By Drug Type
6.1. Vaccines, Antiviral
6.3. Anabolic Steroids
6.5. Anti-Rejection Drugs
6.6. Immunosuppressive Agents
6.7. Immune Globulins
7. Liver Disease Treatment Market, By Disease
7.2. Autoimmune Diseases
7.3. Liver Tumor
7.4. Alcohol Induced Liver Disease
7.5. Chronic Liver Disease
7.6. Non-Alcoholic Fatty Liver Disease
8. Liver Disease Treatment Market, By End-User
8.2. Adult Liver Disease Treatment Centers
8.3. Ambulatory Surgical Centers
9. Liver Disease Treatment Market, By Geography
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.4. Rest of the World (RoW)
9.4.2. Rest of RoW
10. Liver Disease Treatment – Market Entropy
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract
11. Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
11.1. Abbott Laboratories
11.2. Actavis Inc.
11.3. Aton Pharma
11.4. Bayer Schering AG
11.6. Bristol-Myers Squibb
11.7. Eli Lilly
11.8. Forest laboratories, Inc.
11.9. Glaxosmithkline PlC, Merck & Co.
11.15. Takeda Pharmaceuticals
11.16. Zydus Pharmaceuticals Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
12.3. Research Methodology
12.5. Compilation of Expert Insights